This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 9.52% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -10.53% and 1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid
by Zacks Equity Research
Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.
LeMaitre Vascular (LMAT) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Meets Q3 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -7.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
LeMaitre Vascular, Inc. (LMAT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
LeMaitre Vascular, Inc. (LMAT) Sees Hammer Chart Pattern: Time to Buy?
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
by Zacks Equity Research
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
Boost Immunity to Market Volatility With 5 Low-Beta Stocks
by Zacks Equity Research
We have developed a strategy which clearly shows that stocks with low risk could also reward investors with handsome returns.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse portfolio and accretive acquisitions is instrumental in aiding the company's top-line growth.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker Corporation (SYK) has successfully expanded its product portfolio over time, which aids the company to cater to evolving demands of customers.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex Corp (LMNX) is focusing on augmenting its portfolio strength through new FDA approvals.
5 MedTech Stocks to Pick for Stellar Returns
by Zacks Equity Research
While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.
5 Top-Ranked MedTech Growth Stocks for Solid Returns
by Zacks Equity Research
Despite the ongoing turmoil in the MedTech industry, these stocks with high growth potential can be great bets for investors.
Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead
by Zacks Equity Research
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
Why LeMaitre Vascular (LMAT) Could Be Positioned for a Surge
by Zacks Equity Research
LeMaitre Vascular (LMAT) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Top Ranked Momentum Stocks to Buy for August 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 8th:
LeMaitre Vascular (LMAT) Worth a Look: Stock Jumps 19.5%
by Zacks Equity Research
LeMaitre Vascular, Inc. (LMAT) shares jumped above 19% in the last trading session.
Top Ranked Momentum Stocks to Buy for July 31st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 31st:
Time to Focus on LeMaitre Vascular (LMAT) for Strong Earnings Growth Potential
by Zacks Equity Research
LeMaitre Vascular (LMAT) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
7 Stocks to Buy with Impressive Interest Coverage Ratio
by Zacks Equity Research
A company's fundamentals should be sound enough to meet its financial obligations. This can be judged through coverage ratios.
Can The Uptrend Continue for LeMaitre Vascular (LMAT)?
by Zacks Equity Research
Investors certainly have to be happy with LeMaitre Vascular Inc (LMAT) and its short term performance
Top Ranked Momentum Stocks to Buy for April 28th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 28th: